Comparison of rate and rhythm control in hypertension patients with atrial fibrillation

Circulation Journal

Volumn 72, Issue 5, 2008, Pages 705-708

  Yildiz, Ahmet ^a   Yigit, Zerrin ^b   Okcun, Baris ^b   Baskurt, Murat ^c   Ortak, Kadriye ^c   Kaya, Aysem ^b   Kucukoglu, Serdar ^b  

^a Gazi Hospital   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c Hizmet Hospital   (Turkey)

Author keywords

Atrial fibrillation; Cardioversion; Hypertension

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EMBOLISM; EXERCISE; EXERCISE TEST; FEMALE; HEART ATRIUM FIBRILLATION; HEART RATE; HEART RHYTHM; HUMAN; HYPERTENSION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MORTALITY; RANDOMIZED CONTROLLED TRIAL; SINUS RHYTHM; STATISTICAL SIGNIFICANCE;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ATRIAL FIBRILLATION; CALCIUM CHANNEL BLOCKERS; CARDIOTONIC AGENTS; DIGOXIN; ELECTRIC COUNTERSHOCK; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; LOSARTAN; MALE; METOPROLOL; MIDDLE AGED; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VERAPAMIL;

EID: 44149121667     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.72.705     Document Type: Article

References (23)

1. Pai SM, Pai RG. Management of atrial fibrillation. N Engl J Med 1992; 327: 1031; 1031-1032 (Discussion).
2. Hennersdorf MG, Strauer BE. Atrial fibrillation. Internist (Berl) 2006; 47: 990-1000.
3. Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol 2001; 38: 1231-1266.
4. Falk RH. Atrial fibrillation. N Engl J Med 2001; 334: 1067-1077.
5. Verdecchia P, Reboldi G, Gattobigio R, Bentivoglio M, Borgioni C, Angeli F, et al. Atrial fibrillation in hypertension: Predictors and outcome. Hypertension 2003; 41: 218-223.
6. Healey JS, Connolly SJ. Atrial fibrillation: Hypertension as a causative agent, risk factor for complications, and potential therapeutic target. Am J Cardiol 2003; 91: 9-14.
7. Ciaroni S, Cuenoud L, Bloch A. Clinical study to investigate the predictive parameters for the onset of atrial fibrillation in patients with essential hypertension. Am Heart J 2000; 139: 814-819.
8. Chalmers J, MacMahon S, Mancia G, Whitworth J, Berlin L, Hansson L, et al. 1999 World Health Organization - International Society of Hypertension Guidelines for the management of hypertension: Guidelines sub-committee of the World Health Organization. Clin Exp Hypertens 1999; 21: 1009-1060.
9. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 1991; 22: 983-988.
10. Prystowsky EN, Benson DW Jr, Fuster V, Hart RG, Kay GN, Myerburg RJ, et al. Management of patients with atrial fibrillation: A Statement for Healthcare Professionals: From the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. Circulation 1996; 93: 1262-1277.
11. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: The Framingham study. N Engl J Med 1982; 306: 1018-1022.
12. Morley J, Marinchak R, Rials SJ, Kowey P. Atrial fibrillation, anti-coagulation, and stroke. Am J Cardiol 1996; 77: 38A-44A.
13. Cairns JA, Connolly SJ. Nonrheumatic atrial fibrillation: Risk of stroke and role of antithrombotic therapy. Circulation 1991; 84: 469-481.
14. Okin PM, Wachtell K, Devereux RB, Harris KE, Jern S, Kjeldsen SE, et al. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. JAMA 2006; 296: 1242-1248.
15. Hennersdorf MG, Strauer BE. Arterial hypertension and cardiac arrhythmias. J Hypertens 2001; 19: 167-177.
16. AFFIRM Investigators; Atrial Fibrillation Follow-up Investigation of Rhythm Management. Baseline characteristics of patients with atrial fibrillation: The AFFIRM Study. Am Heart J 2002; 143: 991-1001.
17. Epstein AE, Vidaillet H, Greene HL, Curtis AB, Ellenbogen KA, Simmons T, et al. Frequency of symptomatic atrial fibrillation in patients enrolled in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. J Cardiovasc Electrophysiol 2002; 13: 667-671.
18. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, et al; Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-1833.
19. Coletta A, Thackray S, Nikitin N, Cleland JG. Clinical trials update: Highlights of the scientific sessions of The American College of Cardiology 2002: LIFE, DANAMI 2, MADIT-2, MIRACLE-ICD, OVERTURE, OCTAVE, ENABLE 1 & 2, CHRISTMAS, AFFIRM, RACE, WIZARD, AZACS, REMATCH, BNP trial and HARDBALL. Eur J Heart Fail 2002; 3: 381-388.
20. Saxonhouse SJ, Curtis AB. Risks and benefits of rate control versus maintenance of sinus mythm. Am J Cardiol 2003; 91: 27D-32D.
21. Khairy P, Nattel S. New insights into the mechanisms and management of atrial fibrillation. CMAJ 2002; 167: 1012-1020.
22. Louis A, Cleland JG, Crabbe S, Ford S, Thackray S, Houghton T, et al. Clinical Trials Update: CAPRICORN. COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure: Highlights of the Scientific Sessions of the American College of Cardiology, 2001. Eur J Heart Fail 2001; 3: 381-387.
23. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation - Pharmacological Intervention in Atrial Fibrillation (PIAF): A randomised trial. Lancet 2000; 356: 1789-1794.